- Previous Close
0.3670 - Open
0.3670 - Bid 0.3670 x --
- Ask 0.4300 x --
- Day's Range
0.3670 - 0.3670 - 52 Week Range
0.2159 - 0.7246 - Volume
5 - Avg. Volume
6,006 - Market Cap (intraday)
4.57M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York.
accustem.com3
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: ACUT
View More
Performance Overview: ACUT
Trailing total returns as of 2025-01-24, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACUT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACUT
View MoreValuation Measures
Market Cap
4.57M
Enterprise Value
4.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: ACUT
ACUT does not have Company Insights